Affiliation:
1. Qpex Biopharma, Inc., San Diego, California, USA
Abstract
Acinetobacter baumannii
infections are difficult to treat and have limited treatment options. Carbapenems, including meropenem, are currently considered the first-line agents for the treatment of infections caused by
Acinetobacter
spp. The percentage of a 24-hour period that the concentration of free drug in plasma is above the MIC (%24-h
f
T>MIC) to achieve stasis, 1 log CFU, or 2 log CFU of bacterial killing against
A. baumannii
has not been studied previously for meropenem.
Funder
Department of Health and Human Services, Office of the Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献